Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PhRMA v. Florida

Executive Summary

The Pharmaceutical Research & Manufacturers of America's request for a preliminary injunction against Florida Medicaid's preferred drug program will be denied, Tallahassee, Fla. federal court Magistrate Judge William Sherrill says during Sept. 20 hearing. "I don't see that the federal law prohibits a prior authorization program that furthers other state interests...as long as it keeps intact the idea of the [federal Medicaid] formulary," Sherrill said. The program was approved as a Medicaid plan amendment by HHS Sept. 18. Manufacturers are expected to offer supplemental rebates to the state in exchange for having their drugs on the preferred list

You may also be interested in...



GSK Florida Medicaid Deal Close; Discounts Are Not "Difficult," Garnier Says

GlaxoSmithKline's discounts to the Florida state Medicaid program are not out of line with agreements with other states, CEO J.P. Garnier told the Bear Stearns "virtual" healthcare conference Sept. 24.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Latest Headlines
See All
UsernamePublicRestriction

Register

PS038550

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel